Protocol Ledger

NCT06786338 · Phase II · ACTIVE NOT RECRUITING

A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases

Interventional Phase II clinical trial protocol NCT06786338 sponsored by Suzhou Sanegene Bio in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-06-06 Enrollment: 45 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06786338
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)45 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06786338
Protocol FieldVerified Registry Value
NCT IdentifierNCT06786338
Consolidated Lead SponsorSuzhou Sanegene Bio
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment45 participants (ACTUAL)
Registered Start Date2025-06-06
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI